CG Oncology, Inc.

NASDAQ
CGON
Stock
Yield per half year: -27.25%
Dividend yield: 0%

Share chart CG Oncology, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About CG Oncology, Inc.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

more details
It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2024-01-25
ISIN US1569441009
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Цена ао 25.44
Change price per day: 0% (25.28)
Change price per week: -1.86% (25.76)
Change price per month: -6.16% (26.94)
Change price per 3 month: +2.6% (24.64)
Change price per half year: -27.25% (34.75)
Change price per year: -26.7% (34.49)
Change price per year to date: -13.16% (29.11)
All parameters

Grade

Underestimation
Title Value Grade
P/S 1573.67 1
P/BV 2.44 6
P/E 0 0
EV/EBITDA -13.39 0
Total: 2.75
Efficiency
Title Value Grade
ROA, % -18.45 0
ROE, % -19.18 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA -0.0021 10
Total: 9.2
Growth impulse
Title Value Grade
Yield Revenue, % -89.05 0
Yield Ebitda, % 810.34 10
Yield EPS, % 596.69 10
Total: 8
More

Contained in ETF

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Morningstar Small-Cap Growth ETF 0.03872 595.05 0.72598
iShares Morningstar Small-Cap ETF 0.01919 391.25 1.60498
0.03493.151.17

Company management

Head Job title Payment Year of birth
Mr. Arthur Kuan Chairman & CEO 640.97k 1991 (34 years)
Mr. Ambaw Bellete M.S. President & COO 1.06M 1971 (54 years)
Dr. Vijay Kasturi M.D. Chief Medical Officer 212.24k 1968 (57 years)
Ms. Corleen M. Roche CFO & Secretary N/A 1967 (58 years)
Ms. Amy Steele Vice President of Finance, Accounting & Administration N/A
Mr. Swapnil Bhargava Ph.D. Chief Technical Officer N/A
Mr. Bing Kung Vice President of Corporate Development N/A
Mr. Joshua F. Patterson General Counsel & Chief Compliance Officer 1976 (49 years)

About company

Address: United States, Irvine. CA, 400 Spectrum Center Drive - Open in google maps, Open in yandex maps
Website: https://cgoncology.com